Global Alzheimers Drugs Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Alzheimer's Disease and Rising Geriatric Population
![]() |
Alzheimers Drugs Market |
The global Alzheimers drugs market is estimated to be valued at US$ 7 billion in 2022 and is expected to exhibit a CAGR of 9.5% over the forecast period of 2017-2025, as highlighted in a new report published by Coherent Market Insights.
A) Market
Overview:
Alzheimer's disease is a neurodegenerative disorder that affects mainly the elderly population. It is characterized by progressive cognitive impairment, memory loss, and behavioral changes. The market for Alzheimer's drugs includes pharmaceutical products used for the treatment of these symptoms and to slow down the progression of the disease. Key drugs in the market include cholinesterase inhibitors and NMDA receptor antagonists.
B) Market
Dynamics:
The market for Alzheimer's drugs is driven by two main factors. Firstly, the increasing prevalence of Alzheimer's disease globally is contributing to the growth of this market. According to the World Alzheimer Report 2019, there were an estimated 50 million people worldwide living with dementia in 2019, and this number is expected to triple by 2050. Secondly, the rising geriatric population is also a significant driver for this market. With advancements in healthcare, life expectancies have increased, leading to a larger proportion of the population being elderly and at a higher risk of developing Alzheimer's disease.
C) Market
Key Trends:
One key trend in the Alzheimers drugs market is the development of disease-modifying drugs. Currently, most available treatments focus on managing symptoms rather than slowing down or halting the progression of the disease. However, several key players in the Alzheimers Drugs Market are investing in research and development to develop drugs that can modify the course of the disease and provide better outcomes for patients. For example, Biogen is conducting clinical trials for its Alzheimer's drug candidate, Aducanumab, which aims to remove amyloid plaques in the brain, a key characteristic of Alzheimer's disease.
D) SWOT
Analysis:
Strength:
1. Growing
demand for Alzheimer's drugs
2. Advancements in research and development
Weakness:
1. Lack of
curative treatment options
2. High cost of Alzheimer's drugs
Opportunity:
1. Untapped
markets in developing countries
2. Increasing healthcare expenditure
Threats:
1.
Stringent regulations for drug approvals
2. Patent expirations and generic competition
E) Key
Takeaways:
- The
global Alzheimers drugs market is
expected to witness high growth, exhibiting a CAGR of 9.5% over the forecast
period, due to increasing prevalence of Alzheimer's disease and rising
geriatric population.
- North
America is expected to be the fastest growing and dominating region in the
market, driven by the high prevalence of Alzheimer's disease and presence of
key market players.
- Key players operating in the global Alzheimers drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, and Teva Pharmaceuticals Industries Ltd.
In
conclusion, the global Alzheimers drugs market is poised for significant growth due to the
increasing prevalence of Alzheimer's disease and the aging population. The
development of disease-modifying drugs and advancements in research and
development present opportunities for market players to provide more effective
treatments for patients. However, challenges such as the lack of curative
treatment options and high cost of drugs need to be addressed to ensure
accessible and affordable healthcare for individuals suffering from Alzheimer's
disease.
Comments
Post a Comment